Connect with us

PR Newswire

IsoPlexis Strengthens Commercial Leadership with the Appointment of Jason Ou as Asia-Pacific General Manager

Published

on

BRANFORD, Conn., May 13, 2021 /PRNewswire/ — IsoPlexis, the leader in single-cell proteomics, today announced that Jason Ou has joined the company as General Manager for the Asia-Pacific (APAC) region. In this role, Mr. Ou will continue to advance IsoPlexis’ growth and expand the company’s customer base in the APAC region.

“We are pleased to have Jason join our leadership team at IsoPlexis,” said Peter Siesel, Chief Commercial Officer of IsoPlexis. “Jason has an extensive track record of leadership, solution-oriented thinking, and customer satisfaction in the life sciences industry. We are confident that his skills and experience will help IsoPlexis continue to further rapid global growth and innovation.”

Mr. Ou brings more than a decade of leadership, operational, and commercial experience in the life sciences industry to IsoPlexis. He joins IsoPlexis from Tecan, a global provider of automated workflow solutions in the life science and clinical diagnostics markets. Mr. Ou started at Tecan as the OEM Components Business Manager for China & Southeast Asia, before becoming Director of OEM Business for APAC. In his last position with Tecan, Mr. Ou was Head of Market Unit Commercial Operations, AP (General Manager APAC). 

“I am very excited to join the IsoPlexis team,” said Jason Ou. “Isoplexis provides incredible technology for single-cell proteomics to bridge the gap for accelerating advanced medicines. I look forward to working with this extraordinarily talented team to bring such groundbreaking technology into APAC region. I am proud to be part of this journey.”

ABOUT ISOPLEXIS:

IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. Our integrated systems, named top innovation or design by the Scientist Magazine, Fierce, BIG Innovation, Red Dot & multiple others, are used globally to advance the field of single-cell biology into new ‘omic possibilities, as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been adopted by researchers around the world, including the top 15 global pharmaceutical companies and by 45% of comprehensive cancer centers in the U.S.. Visit http://www.isoplexis.com to learn more.

MEDIA CONTACT:

Jon Chen VP of Marketing IsoPlexis
[email protected]

SOURCE IsoPlexis

Related Links

http://www.isoplexis.com

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/isoplexis-strengthens-commercial-leadership-with-the-appointment-of-jason-ou-as-asia-pacific-general-manager-301290849.html

PR Newswire

Perfect World to pioneer digital culture and creative sector in joint hands with partners

Published

on

As a world’s leading entertainment group, Perfect World proposed “Creative Thinking” strategy, aiming at breaking the barrier of the real world and virtual world, and combining new types of games with traditional industries so as to empower the development of traditional industries and promote digital upgrade of traditional industries as well.

Under the “Creative Thinking” strategy, Perfect World has made significant achievements in its cooperation with enterprises and institutions, such as implanting scenes of the Qinhuai Lantern Fair of Nanjing Confucius Temple into its famous game “Zhuxian,” and the collaboration between its mobile game Chronicle of Infinity and the famous sports brand Peak.

Perfect World CEO Dr. Robert H. Xiao said at the conference that after all the successful cases, Perfect World has been more confident about cross-over cooperation between digital culture industry and traditional industries. He promised that Perfect World will keep exploring to establish a value chain that empowers traditional industries, and incubate more new types of culture content, products, and business models.

In its collaboration with Nianhuawan scenic spot in Wuxi, Perfect World gamified the scenic spots, and brought tourists an immersive experience by combing the scenic spot and the digital world. The move helps the scenic spot to upgrade from service-based economic to experience economy.

“Not only will we explore subdivided fields with partners, but also work as a bridge to promote cross-over cooperation among companies in various fields, so as to achieve common development,” said Dr. Xiao. “And we hope to joint hands with our partners to unlock a new track in this ‘experimental production’ of the culture industry that faces the future,” he added.

Perfect World will tailor a whole set of solutions and plans on digital upgrading partners’ products based on their requirements. For example, in its cooperation with Shanghai Science and Technology Museum, Perfect World will develop a game to turn the complicated scientific knowledge into visions to help readers understand the scientific knowledge. The Group will also have an in-depth cooperation with China Audio-video and Digital Publishing Association in the field of education and vocational training such as e-sports talent cultivation.

The culture department of Beijing’s Dongcheng district, People’s Cultural Tourism of People’s Daily, a cultural & creative institute affiliated to Tsinghua University, Beijing Dongsheng Bozhan Cloud Computing Technology Co., Ltd., and Nianhuawan scenic spot, also signed strategic cooperation agreements with Perfect World in the brand cooperation conference.

SOURCE Perfect World

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/perfect-world-to-pioneer-digital-culture-and-creative-sector-in-joint-hands-with-partners-301311222.html

Continue Reading

PR Newswire

European Hematology Association : la réponse humorale au vaccin Pfizer/BioNTech BNT162b2 est altérée chez les patients recevant un CAR-T ou un traitement immunosuppresseur de haute intensité

Published

on

LA HAYE, Pays-Bas, 12 juin 2021 /PRNewswire/ — Le vaccin Pfizer/BioNTech BNT162b2 a été approuvé pour la prévention de l’infection par le coronavirus 2 du syndrome respiratoire aigu sévère (SRAS-CoV-2) et est recommandé pour les patients immunodéprimés. Cependant, son efficacité et son innocuité chez les patients suivant une thérapie cellulaire immunologique n’ont pas été bien documentées. Dans le cadre de cette étude, nous avons évalué l’efficacité et l’innocuité du vaccin BNT162b2 chez les patients ayant subi une greffe de cellules hématopoïétiques (HCT) et un traitement au récepteur d’antigène chimérique (CAR)-T. Nous avons suivi prospectivement 79 patients vaccinés ayant été activement traités au Centre médical Sourasky de Tel Aviv et surveillé le profil d’innocuité et la réponse immunitaire humorale au vaccin.

Dans l’ensemble, le vaccin a été bien toléré et tous les effets indésirables se sont résorbés en quelques jours, à l’exception d’un rejet de greffe secondaire, qui fait toujours l’objet d’une enquête. Nous avons observé que seulement 36 % des patients ayant reçu un traitement CAR-T ont développé une réponse aux anticorps humoraux comparativement à 81 % des patients ayant subi une TSS allogénique. De plus, les patients atteints d’aplasie des cellules B et ceux ayant reçu le vaccin peu après la perfusion de cellules étaient moins susceptibles de développer des anticorps. Prises ensemble, ces données démontrent que la réponse humorale au vaccin BNT162b2 est significativement altérée chez les patients recevant le CAR-T, par opposition à ceux ayant reçu une TSS allogénique ayant une bonne réponse.

Présentateur : Professeur Ron Ram

Affiliation : Unité BMT, Tel Aviv Sourasky Medical Center, Tel Aviv, Israël

Résumé : #S285 INNOCUITÉ ET EFFICACITÉ DU VACCIN BNT162B2 MRNA COVID-19 CHEZ LES PATIENTS APRÈS UNE THÉRAPIE ALLOGÉNIQUE À BASE DE HCT ET DE CD19 – ÉTUDE DE COHORTE PROSPECTIVE À UN SEUL CENTRE

À propos du congrès annuel de l’AEH : Chaque année, en juin, l’AEH organise son congrès annuel dans une grande ville européenne. Cette année, en raison de la persistance de la pandémie de COVID-19, l’AEH organise pour la deuxième fois un Congrès virtuel. Le Congrès s’adresse aux professionnels de santé travaillant dans le domaine de l’hématologie ou s’y intéressant. Les sujets du programme scientifique vont de la physiologie et du développement des cellules souches à la leucémie, le lymphome, le diagnostic et le traitement, les globules rouges, les globules blancs et les troubles plaquettaires, l’hémophilie et le myélome, la thrombose et les troubles de la coagulation ainsi que la transfusion et la transplantation de cellules souches.

Site web :www.ehaweb.org

Logo – https://mma.prnewswire.com/media/622259/EHA_Logo.jpg

SOURCE European Hematology Association (EHA)

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/european-hematology-association-la-reponse-humorale-au-vaccin-pfizer-biontech-bnt162b2-est-alteree-chez-les-patients-recevant-un-car-t-ou-un-traitement-immunosuppresseur-de-haute-intensite-862309567.html

Continue Reading

PR Newswire

EHA:Eficacia de la vacuna Pfizer/BioNTech BNT162b2 en pacientes que reciben CAR-T

Published

on

– European Hematology Association:La respuesta humoral a la vacuna Pfizer/BioNTech BNT162b2 se ve afectada en pacientes que reciben CAR-T o terapia inmunosupresora de alta intensidad

LA HAYA, Países Bajos, 12 de junio de 2021 /PRNewswire/ — La vacuna Pfizer/BioNTech BNT162b2 ha sido aprobada para la prevención del síndrome respiratorio agudo severo por coronavirus 2 (SARS-CoV-2) y se recomienda para pacientes inmunosuprimidos. Sin embargo, su eficacia y seguridad en pacientes sometidos a terapia celular inmunológica no han sido bien documentadas. En este estudio, evaluamos la eficacia y seguridad de la vacuna BNT162b2 en pacientes que se sometieron a trasplante de células hematopoyéticas (HCT) y terapia con receptor de antígeno quimérico (CAR) -T. Seguimos prospectivamente a 79 pacientes vacunados que fueron tratados activamente en el Centro Médico Sourasky de Tel Aviv y monitoreamos el perfil de seguridad y la respuesta inmune humoral a la vacuna.

En general, la vacuna fue bien tolerada y todos los efectos secundarios se resolvieron en unos pocos días, excepto un rechazo secundario del injerto, que aún está bajo investigación. Observamos que solo el 36% de los pacientes que recibieron terapia CAR-T desarrollaron una respuesta humoral de anticuerpos en comparación con el 81% de los pacientes que se sometieron a un HCT alogénico. Además, los pacientes con aplasia de células B y los que recibieron la vacuna poco después de la infusión de células tenían menos probabilidades de desarrollar anticuerpos. Tomados en conjunto, estos datos demuestran que la respuesta humoral a la vacuna BNT162b2 está significativamente alterada en los pacientes que reciben CAR-T, a diferencia de aquellos después de un HCT alogénico que tuvieron una buena respuesta.

Presentador:  Profesor Ron Ram

Afiliación:  BMT Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Abstract: #S285  SAFETY AND EFFICACY OF THE BNT162B2 MRNA COVID-19 VACCINE IN PATIENTS AFTER ALLOGENEIC HCT AND CD19-BASED CAR-T THERAPY – A SINGLE CENTER PROSPECTIVE COHORT STUDY

Acerca del Congreso anual de EHA: Cada junio, la EHA organiza su Congreso Anual en una de las principales ciudades europeas. Este año, debido a la persistente pandemia de COVID19, EHA organiza un Congreso virtual por segunda vez. El Congreso está dirigido a profesionales de la salud que trabajen o estén interesados en el campo de la hematología. Los temas del programa científico van desde la fisiología y el desarrollo de las células madre hasta la leucemia; linfoma diagnostico y tratamiento; las células rojas de la sangre; trastornos de los glóbulos blancos y las plaquetas; hemofilia y mieloma; trombosis y trastornos hemorrágicos; así como transfusión y trasplante de células madre.

Sitio web: www.ehaweb.org

Logo – https://mma.prnewswire.com/media/622259/EHA_Logo.jpg

SOURCE European Hematology Association (EHA)

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/eha-eficacia-de-la-vacuna-pfizer-biontech-bnt162b2-en-pacientes-que-reciben-car-t-868759422.html

Continue Reading

PR Newswire

European Hematology Association: Overall Survival Benefit Established With Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) in Elderly Patients with Transplant-ineligible Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Interim Analysis of the MAIA Study

Published

on

THE HAGUE, Netherlands, June 12, 2021 /PRNewswire/ — The phase 3 MAIA study evaluated D-Rd versus Rd in 737 patients who were ineligible for high-dose chemotherapy and autologous stem cell transplantation. The primary analysis of MAIA demonstrated a 44% reduction in the risk of disease progression or death after treatment with D-Rd compared with Rd alone. At a median follow-up of almost 5 years (56.2 months), we now report the pre-specified interim overall survival analysis of MAIA.

The addition of daratumumab to Rd treatment significantly reduced the risk of death by 32% (hazard ratio, 0.68; 95% confidence interval [CI], 0.53-0.86; P=0.0013) with an estimated 5-year overall survival rate of 66.3% in the D-Rd group compared with 53.1% in the Rd alone group. These results are despite 46% of patients who received subsequent therapy in the Rd arm receiving daratumumab. Similarly, the significant progression-free survival benefit of D-Rd versus Rd that was identified in the primary analysis was maintained, with a 47% reduction in the risk of disease progression or death (HR, 0.53; 95% CI, 0.43-0.66; P<0.0001) and an estimated 60-month progression-free survival rate of 52.5% versus 28.7%, respectively; these data provide a new PFS benchmark for patients with NDMM who are transplant ineligible. The high overall response rate (93% vs 82%) further demonstrated the added clinical benefit of D-Rd versus Rd alone. No new safety concerns were identified for D-Rd and the most common (>15%) grade 3/4 treatment-emergent adverse events for D-Rd and Rd were neutropenia (54% vs 37%), pneumonia (19% vs 11%), anemia (17% vs 22%), and lymphopenia (16% and 11%). In conclusion, the clinical benefit from the primary analysis of the MAIA study was maintained through 5 years of follow-up and the benefit of upfront D-Rd given to progression was confirmed with a significant OS improvement, further supporting the use of frontline daratumumab as a new standard of care for patients with transplant-ineligible NDMM.

The results of this study will be presented by Prof. Thierry Facon on Saturday, June 12.

Presenter: Professor Thierry Facon

Affiliation: University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France

Abstract: #LB1901 OVERALL SURVIVAL RESULTS WITH DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 3 MAIA STUDY

About the EHA Annual Congress: Every year in June, EHA organizes its Annual Congress in a major European city. This year due to the persisting COVID19 pandemic, EHA organized a Virtual Congress for the second time. The Congress is aimed at health professionals working in or interested in the field of hematology.

Website: www.ehaweb.org

Logo – http://mma.prnewswire.com/media/622259/EHA_Logo.jpg

SOURCE European Hematology Association (EHA)

Related Links

https://ehaweb.org/

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/european-hematology-association-overall-survival-benefit-established-with-daratumumab-plus-lenalidomide-and-dexamethasone-d-rd-in-elderly-patients-with-transplant-ineligible-newly-diagnosed-multiple-myeloma-ndmm-long-term-in-301310175.html

Continue Reading
Aviation4 days ago

The Story Of The Boeing 777 Family

zephyrnet5 days ago

7th Global Blockchain Congress by Agora Group & TDeFi on June 21st and 22nd, 2021, Dubai.

Big Data5 days ago

.NET DEVELOPMENT

Crowdfunding4 days ago

April/May 2021 Top Campaigns

Blockchain5 days ago

Woonkly will be the official Title Sponsor of the 7th edition Global Blockchain Congress organized by Agora Group in Dubai

Blockchain5 days ago

Death Cross is Appearing Over Bitcoin Price Chart

Esports4 days ago

Every new Passive Power in Legends of Runeterra Lab of Legends 2.9.0

Crowdfunding5 days ago

US Fintech Broadridge Partners with Amazon Web Services to Expand Private Market Hub, Leveraging DLT

Big Data5 days ago

China arrests over 1,100 suspects in crackdown on crypto-related money laundering

Blockchain4 days ago

Crypto Fund Manager Says Bitcoin ETFs to be Approved By 2022

Gaming5 days ago

TrustDice Review: Features & Promotions

Aviation1 day ago

Delta Air Lines Flight Diverts To Oklahoma Over Unruly Off-Duty Flight Attendant

Esports2 days ago

Lost Ark Founders Pack: Everything You Need to Know

Fintech4 days ago

PayPal launches PayPal Rewards Card in Australia

Cleantech5 days ago

TC Energy Cancels Keystone XL Pipeline

Energy3 days ago

Industrial robots market in the automotive industry | $ 3.97 billion growth expected during 2021-2025 | 17000+ Technavio Research Reports

Cyber Security3 days ago

Data Breach that Impacted Both Audi of America and Volkswagen of America

Energy3 days ago

Daiki Axis Co., Ltd. (4245, First Section, Tokyo Stock Exchange) Overview of Operating Performance for the First Three Months Ended March 31, 2021

Cleantech3 days ago

Tesla Model S 420 Plaid Is The Best Car In The World (But Not For Me)

Aviation1 day ago

Spirit Airlines Just Made The Best Argument For Lifting LaGuardia’s Perimeter Rule

Trending